Journals A-Z
All Subjects
Free Journals
sciepub.com
American Journal of Medical and Biological Research
ISSN (Print): 2328-4080 ISSN (Online): 2328-4099 Website: https://www.sciepub.com/journal/ajmbr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
Issue 4, Volume 1
Article Metrics
  • 52369
    Views
  • 48572
    Saves
  • 0
    Citations
  • 36
    Likes
Export Article
American Journal of Medical and Biological Research. 2013, 1(4), 149-158
DOI: 10.12691/ajmbr-1-4-8
Open AccessReview Article

Comparative Genomic Hybridization Studies on Mesothelioma Show a Parallel Fate of 1p21-1p22 and 9p21 Bands and a Chromosomally Stable Sub-Group

Melaiu Ombretta1, Bracci Elisa1, Cristaudo Alfonso2, Bonotti Alessandra2, Foddis Rudy2, Mutti Luciano3, Gemignani Federica1 and Landi Stefano1,

1Department of Biology, University of Pisa, Pisa, Italy

2Department of Endocrinology and Metabolism, Orthopedics and Traumatology, Occupational Medicine, University of Pisa, Pisa, Italy

3Mutti Luciano, Laboratory of Clinical Oncology, Vercelli National Health Trust, Vercelli, Italy

Pub. Date: December 19, 2013
View Full Text Full Text PDF (755 KB) Full Text ePUB(1327 KB)

Cite this paper:
Melaiu Ombretta, Bracci Elisa, Cristaudo Alfonso, Bonotti Alessandra, Foddis Rudy, Mutti Luciano, Gemignani Federica and Landi Stefano. Comparative Genomic Hybridization Studies on Mesothelioma Show a Parallel Fate of 1p21-1p22 and 9p21 Bands and a Chromosomally Stable Sub-Group. American Journal of Medical and Biological Research. 2013; 1(4):149-158. doi: 10.12691/ajmbr-1-4-8

Abstract

Malignant Pleural Mesothelioma (MPM) is a cancer whit a poor prognosis. The landscape of the chromosomal rearrangements in MPM was approached by several authors but robust conclusions could not be made, given the limited sample sets analyzed within each study. In order to improve the knowledge on the field, we retrieved and pooled all the results deriving from published studies where comparative genomic hybridization (CGH) was employed. A total of 283 tissues (149 epithelioid, 53 sarcomatoid, 78 biphasic, and 3 unclassified) were analysed, 179 with classical chromosome CGH (cCGH), and 104 with arrayed-CGH (aCGH). Some chromosomal bands were involved in aberrations with a frequency exceeding 20% (-1p21, -9p, -14q, and -22q for the epithelioid, -4, +5p, +8q21àter, -9p, -13, and -14q for the sarcomatoid, and -9p, -14q, and -22q for the biphasic type). We found a statistical significant association between contemporary losses at 9p21 and 1p21-1p22 (21% of the samples showed losses at both bands, P=7.74x10-8), whose significance should be elucidated with further studies. Candidate cancer genes involved in MPM were suggested. Finally, 15% of epithelioid, 13% of sarcomatoid, and 13% of biphasic MPM tissues did not show any genomic alteration. Only two previous studies suggested a less aggressive behavior of MPM in relation to a low degree of chromosomal alterations. Thus, more work is warranted to understand whether chromosomal rearrangements could be included as prognostic biomarker in the clinical practice.

Keywords:
comparative genomic hybridization mesothelioma chromosomal instability tumor suppressor genes chromosomal gain chromosomal loss

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 25

References:

[1]  Carbone, M., Kratzke, R. A., and Testa, J. R., “The pathogenesis of mesothelioma,” Semin.Oncol., 29 (1). 2-17. Feb. 2002.
 
[2]  Carbone, M. and Bedrossian, C. W., “The pathogenesis of mesothelioma,” Semin.Diagn.Pathol., 23 (1). 56-60. Feb. 2006.
 
[3]  Zucali, P. A. and Giaccone, G., “Biology and management of malignant pleural mesothelioma,” Eur.J.Cancer, 23 (1). 56-60. Feb. 2006.
 
[4]  Cristaudo, A., Foddis, R., Vivaldi, A., Buselli, R., Gattini, V., Guglielmi, G., Cosentino, F., Ottenga, F., Ciancia, E., Libener, R., Filiberti, R., Neri, M., Betta, P., Tognon, M., Mutti, L., and Puntoni, R., “SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study,” Cancer Res., 65 (8). 3049-52. Apr. 2005.
 
[5]  Roushdy-Hammady, I., Siegel, J., Emri, S., Testa, J. R., and Carbone, M., “Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey,” Lancet, 357 (9254). 444-5. Feb. 2001.
 
[6]  Gordon, G. J., Rockwell, G. N., Godfrey, P. A., Jensen, R. V., Glickman, J. N., Yeap, B. Y., Richards, W. G., Sugarbaker, D. J., and Bueno, R., “Validation of genomics-based prognostic tests in malignant pleural mesothelioma,” Clin.Cancer Res., 11 (12). 4406-14. Jun. 2005.
 
[7]  Jean, D., Thomas, E., Manié, E., Renier, A., de Reynies, A., Lecomte, C., Andujar, P., Fleury-Feith, J., Galateau-Sallé, F., Giovannini, M., Zucman-Rossi, J., Stern, M. H., and Jaurand, M. C., “Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma,” Am.J.Pathol., 178 (2). 881-94. Feb. 2011.
 
[8]  Andrieux, J. and Sheth, F., “Comparative genomic hybridization array study and its utility in detection of constitutional and acquired anomalies,” Indian J.Exp.Biol., 47 (10). 779-91. Oct. 2009.
 
[9]  Klorin, G., Rozenblum, E., Glebov, O., Walker, R. L., Park, Y., Meltzer, P. S., Kirsch, I. R., Kaye, F. J., and Roschke, A.V. “Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines,” Cancer Genet. 206(5):191-205. May 2013.
 
[10]  Yoshikawa, Y., Sato, A., Tsujimura, T., Morinaga, T., Fukuoka, K., Yamada, S., Murakami, A., Kondo, N., Matsumoto, S., Okumura, Y., Tanaka, F., Hasegawa, S., Hashimoto-Tamaoki, T., and Nakano, T., “Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells,” Int.J.Oncol., 39 (6). 1365-74. Dec. 2011.
 
[11]  Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., Hesdorffer, M., Nasu, M., Powers, A., Rivera, Z., Comertpay, S., Tanji, M., Gaudino, G., Yang, H., and Carbone, M., “Germline BAP1 mutations predispose to malignant mesothelioma,” Nat.Genet., 43 (10). 1022-5. Oct. 2011.
 
[12]  12. Shivapurkar, N., Virmani, A. K., Wistuba, I. I., Milchgrub, S., Mackay, B., Minna, J. D., and Gazdar, A. F., “Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma,” Clin.Cancer Res., 5 (1). 17-23. Jan. 1999.
 
[13]  Jiang, L. X., Xu, J., Wang, Z. W., Li, D. P., Peng, Z. H., Gao, J. J., He, L., and Zheng, H. T., “Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma,” World J.Gastroenterol., 14 (36). 5606-11. Sep. 2008.
 
[14]  Borkosky, S. S., Gunduz, M., Nagatsuka, H., Beder, L. B., Gunduz, E., Ali, M. A., Rodriguez, A. P., Cilek, M. Z., Tominaga, S., Yamanaka, N., Shimizu, K., and Nagai, N., “Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma,” J.Cancer Res.Clin.Oncol., 135 (5). 703-13. May. 2009.
 
[15]  Kuiper, R. P., Vreede, L., Venkatachalam, R., Ricketts, C., Kamping, E., Verwiel, E., Govaerts, L., Debiec-Rychter, M., Lerut, E., van Erp, F., Hoogerbrugge, N., van Kempen, L., Schoenmakers, E. F., Bonne, A., Maher, E. R., and Geurts van Kessel, A., “The tumor suppressor gene FBXW7 is disrupted by a constitutional t(3;4)(q21;q31) in a patient with renal cell cancer,” Cancer Genet.Cytogenet., 195 (2). 105-11. Dec. 2009.
 
[16]  Zhang, H., Ma, H., Wang, Q., Chen, M., Weng, D., Wang, H., Zhou, J., Li, Y., Sun, J., Chen, Y., Liang, X., Zhao, J., Pan, K., Wang, H., and Xia, J., “Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array,” Oncol.Rep., 23 (2). 445-55. Feb. 2010.
 
[17]  Tatarano, S., Chiyomaru, T., Kawakami, K., Enokida, H., Yoshino, H., Hidaka, H., Yamasaki, T., Kawahara, K., Nishiyama, K., Seki, N., and Nakagawa, M., “miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer,” Int.J.Oncol., 39 (1). 13-21. Jul. 2011.
 
[18]  Dompe, N., Rivers, C. S., Li, L., Cordes, S., Schwickart, M., Punnoose, E. A., Amler, L., Seshagiri, S., Tang, J., Modrusan, Z., and Davis, D. P., “A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis,” Proc.Natl.Acad.Sci.U.S.A, 108 (43). E943-E951. Oct. 2011.
 
[19]  Kobayashi, M., Huang, C. L., Sonobe, M., Kikuchi, R., Ishikawa, M., Kitamura, J., Miyahara, R., Menju, T., Iwakiri, S., Itoi, K., Yasumizu, R., and Date, H. “Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients,” Exp Ther Med. 3(6):952-958. Jun. 2012.
 
[20]  Schleicher, C., Poremba, C., Wolters, H., Schäfer, K. L., Senninger, N., and Colombo-Benkmann, M., “Gain of chromosome 8q: a potential prognostic marker in resectable adenocarcinoma of the pancreas?,” Ann.Surg.Oncol., 14 (4). 1327-35. Apr. 2007.
 
[21]  Klatte, T., Kroeger, N., Rampersaud, E. N., Birkhäuser, F. D., Logan, J. E., Sonn, G., Riss, J., Rao, P. N., Kabbinavar, F. F., Belldegrun, A. S., and Pantuck, A. J., “Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma,” Cancer, May. 2012.
 
[22]  Zhang, X., Chen, Q., He, C., Mao, W., Zhang, L., Xu, X., Zhu, J., and Chen, B., “Polymorphisms on 8q24 are associated with lung cancer risk and survival in han chinese,” PLoS.One., 7 (7). e41930. 2012.
 
[23]  Joung, J. Y., Park, S., Yoon, H., Lee, S. J., Park, W. S., Seo, H. K., Chung, J., Kim, S. Y., Hong, S. H., Lee, Y. S., Kim, J., and Lee, K. H., “Association of common variations of 8q24 with the risk of prostate cancer in Koreans and a review of the Asian population,” BJU.Int., May. 2012.
 
[24]  Ma, Z., Hu, Q., Chen, Z., Tao, S., Macnamara, L., Kim, S. T., Tian, L., Xu, K., Ding, Q., Zheng, S. L., Sun, J., Xia, G., and Xu, J., “Systematic evaluation of bladder cancer risk-associated single-nucleotide polymorphisms in a Chinese population,” Mol.Carcinog., Jun. 2012.
 
[25]  Dai, J., Gu, J., Huang, M., Eng, C., Kopetz, E. S., Ellis, L. M., Hawk, E., and Wu, X., “GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes,” Carcinogenesis, 33 (7). 1327-31. Jul. 2012.
 
[26]  Bertucci, F., Lagarde, A., Ferrari, A., Finetti, P., Charafe-Jauffret, E., Van Laere, S., Adelaide, J., Viens, P., Thomas, G., Birnbaum, D., and Olschwang, S., “8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer,” PLoS.One., 7 (5). e37943. 2012.
 
[27]  Vita, M. and Henriksson, M., “The Myc oncoprotein as a therapeutic target for human cancer,” Semin.Cancer Biol., 16 (4). 318-30. Aug. 2006.
 
[28]  Murakami, H., Mizuno, T., Taniguchi, T., Fujii, M., Ishiguro, F., Fukui, T., Akatsuka, S., Horio, Y., Hida, T., Kondo, Y., Toyokuni, S., Osada, H., and Sekido, Y., “LATS2 is a tumor suppressor gene of malignant mesothelioma,” Cancer Res., 71 (3). 873-83. Feb. 2011.
 
[29]  Björkqvist, A. M., Wolf, M., Nordling, S., Tammilehto, L., Knuuttila, A., Kere, J., Mattson, K., and Knuutila, S., “Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis,” Br.J.Cancer, 81 (7). 1111-5. Dec. 1999.
 
[30]  Tabata, C., Hirayama, N., Tabata, R., Yasumitsu, A., Yamada, S., Murakami, A., Iida, S., Tamura, K., Fukuoka, K., Kuribayashi, K., Terada, T., and Nakano, T. “A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma,” Eur Respir J.36(5):1099-105. Nov.2010.
 
[31]  Flejter, W. L., Li, F. P., Antman, K. H., and Testa, J. R., “Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes,” Genes Chromosomes.Cancer, 1 (2). 148-54. Nov. 1989.
 
[32]  Hansteen, I. L., Hilt, B., Lien, J. T., Skaug, V., and Haugen, A., “Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report,” Cancer Genet.Cytogenet., 70 (2). 94-8. Oct. 1993.
 
[33]  Taguchi, T., Jhanwar, S. C., Siegfried, J. M., Keller, S. M., and Testa, J. R., “Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma,” Cancer Res., 53 (18). 4349-55. Sep. 1993.
 
[34]  Bianchi, A. B., Mitsunaga, S. I., Cheng, J. Q., Klein, W. M., Jhanwar, S. C., Seizinger, B., Kley, N., Klein-Szanto, A. J., and Testa, J. R., “High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas,” Proc.Natl.Acad.Sci.U.S.A, 92 (24). 10854-8. Nov. 1995.
 
[35]  Schipper, H., Papp, T., Johnen, G., Pemsel, H., Bastrop, R., Müller, K. M., Wiethege, T., Jaworska, M., Krismann, M., Schiffmann, D., and Rahman, Q., “Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas,” Int.J.Oncol., 22 (5). 1009-17. May. 2003.
 
[36]  Metcalf, R. A., Welsh, J. A., Bennett, W. P., Seddon, M. B., Lehman, T. A., Pelin, K., Linnainmaa, K., Tammilehto, L., Mattson, K., Gerwin, B. I., and Harris, C. C., “p53 and Kirsten-ras mutations in human mesothelioma cell lines,” Cancer Res., 52 (9). 2610-5. May. 1992.
 
[37]  Deguen, B., Goutebroze, L., Giovannini, M., Boisson, C., van der Neut, R., Jaurand, M. C., and Thomas, G., “Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene,” Int.J.Cancer, 77 (4). 554-60. Aug. 1998.
 
[38]  Baser, M. E., De Rienzo, A., Altomare, D., Balsara, B. R., Hedrick, N. M., Gutmann, D. H., Pitts, L. H., Jackler, R. K., and Testa, J. R., “Neurofibromatosis 2 and malignant mesothelioma,” Neurology, 59 (2). 290-1. Jul. 2002.
 
[39]  Fleury-Feith, J., Lecomte, C., Renier, A., Matrat, M., Kheuang, L., Abramowski, V., Levy, F., Janin, A., Giovannini, M., and Jaurand, M. C., “Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours,” Oncogene, 22 (24). 3799-805. Jun. 2003.
 
[40]  Chiosea, S., Krasinskas, A., Cagle, P. T., Mitchell, K. A., Zander, D. S., and Dacic, S., “Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas,” Mod.Pathol., 21 (6). 742-7. Jun. 2008.
 
[41]  Prins, J. B., Williamson, K. A., Kamp, M. M., Van Hezik, E. J., Van der Kwast, T. H., Hagemeijer, A., and Versnel, M. A., “The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma,” Int.J.Cancer, 75 (4). 649-53. Feb. 1998.
 
[42]  Ivanchuk, S. M., Mondal, S., Dirks, P. B., and Rutka, J. T., “The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth,” J.Neurooncol., 51 (3). 219-29. Feb. 2001.
 
[43]  Gil, J. and Peters, G., “Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all,” Nat.Rev.Mol.Cell Biol., 7 (9). 667-77. Sep. 2006.
 
[44]  Zucali, P. A. and Giaccone, G., “Biology and management of malignant pleural mesothelioma,” Eur.J.Cancer, 42 (16). 2706-14. Nov. 2006.
 
[45]  Sekido, Y., “Molecular biology of malignant mesothelioma,” Environ.Health Prev.Med., 13 (2). 65-70. Mar. 2008.
 
[46]  Lee, W. C., Balsara, B., Liu, Z., Jhanwar, S. C., and Testa, J. R., “Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma,” Cancer Res., 56 (19). 4297-301. Oct. 1996.
 
[47]  Li, X., Isono, K., Yamada, D., Endo, T. A., Endoh, M., Shinga, J., Mizutani-Koseki, Y., Otte, A. P., Casanova, M., Kitamura, H., Kamijo, T., Sharif, J., Ohara, O., Toyada, T., Bernstein, B. E., Brockdorff, N., and Koseki, H., “Mammalian polycomb-like Pcl2/Mtf2 is a novel regulatory component of PRC2 that can differentially modulate polycomb activity both at the Hox gene cluster and at Cdkn2a genes,” Mol.Cell Biol., 31 (2). 351-64. Jan. 2011.
 
[48]  Taniguchi, T., Karnan, S., Fukui, T., Yokoyama, T., Tagawa, H., Yokoi, K., Ueda, Y., Mitsudomi, T., Horio, Y., Hida, T., Yatabe, Y., Seto, M., and Sekido, Y. “Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32,” Cancer Sci. 98(3):438-46. Mar. 2007.
 
[49]  Lindholm, P. M., Salmenkivi, K., Vauhkonen, H., Nicholson, A. G., Anttila, S., Kinnula, V. L., and Knuutila, S., “Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH,” Cytogenet.Genome Res., 119 (1-2). 46-52. 2007.
 
[50]  Björkqvist, A. M., Tammilehto, L., Nordling, S., Nurminen, M., Anttila, S., Mattson, K., and Knuutila, S., “Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung,” Br.J.Cancer, 77 (2). 260-9. 1998.
 
[51]  Tiainen, M., Rautonen, J., Pyrhönen, S., Tammilehto, L., Mattson, K., and Knuutila, S., “Chromosome number correlates with survival in patients with malignant pleural mesothelioma,” Cancer Genet.Cytogenet., 62 (1). 21-4. Aug.1992.
 
[52]  Kivipensas, P., Björkqvist, A. M., Karhu, R., Pelin, K., Linnainmaa, K., Tammilehto, L., Mattson, K., Kallioniemi, Q. P., and Knuutila, S., “Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization,” Cancer Genet.Cytogenet., 89 (1). 7-13. Jul. 1996.
 
[53]  Björkqvist, A. M., Tammilehto, L., Anttila, S., Mattson, K., and Knuutila, S., “Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma,” Br.J.Cancer, 75 (4). 523-7. 1997.
 
[54]  Ascoli, V., Aalto, Y., Carnovale-Scalzo, C., Nardi, F., Falzetti, D., Mecucci, C., and Knuutila, S., “DNA copy number changes in familial malignant mesothelioma,” Cancer Genet.Cytogenet., 127 (1). 80-2. May. 2001.
 
[55]  Krismann, M., Müller, K. M., Jaworska, M., and Johnen, G., “Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases,” J.Pathol., 197 (3). 363-71. Jul. 2002.
 
[56]  Musti, M., Cavone, D., Aalto, Y., Scattone, A., Serio, G., and Knuutila, S., “A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly,” Cancer Genet.Cytogenet., 138 (1). 73-6. Oct. 2002.
 
[57]  Simon, F., Johnen, G., Krismann, M., and Müller, K. M., “Chromosomal alterations in early stages of malignant mesotheliomas,” Virchows Arch., 447 (4). 762-7. Oct. 2005.
 
[58]  Knuuttila, A., Jee, K. J., Taskinen, E., Wolff, H., Knuutila, S., and Anttila, S., “Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases,” Virchows Arch., 448 (2). 135-41. Feb. 2006.
 
[59]  Scattone, A., Pennella, A., Gentile, M., Musti, M., Nazzaro, P., Buonadonna, A. L., Marzullo, A., Cavone, D., Pollice, L., and Serio, G., “Comparative genomic hybridisation in malignant deciduoid mesothelioma,” J.Clin.Pathol., 59 (7). 764-9. Jul. 2006.
 
[60]  Ivanov, S. V., Miller, J., Lucito, R., Tang, C., Ivanova, A.V., Pei, J., Carbone, M., Cruz, C., Beck, A., Webb, C., Nonaka, D., Testa, J.R., and Pass, H. I. “Genomic events associated with progression of pleural malignant mesothelioma,” Int J Cancer. 1;124(3):589-99. Feb. 2009.
 
[61]  Balsara, B. R., Bell, D. W., Sonoda, G., De Rienzo, A., du Manoir, S., Jhanwar, S. C., and Testa, J. R. “Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma,” Cancer Res. 15;59(2):450-4. Jan. 1999.
 
[62]  Jean, D., Thomas, E., Manié, E., Renier, A., de Reynies, A., Lecomte, C., Andujar, P., Fleury-Feith, J., Galateau-Sallé, F., Giovannini, M., Zucman-Rossi, J., Stern, M. H., and Jaurand, M. C. “Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma,” Am J Pathol.178(2):881-94. Feb. 2011.
 
Manuscript template